711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.